Atherosclerotic cardiovascular disease (ASCVD) risk is currently determined using the lipid profile with an emphasis on the levels of LDL and high-density lipoprotein (HDL) [[11]]. Cholesterol and lipid metabolism is a broad topic that encompasses multiple aspects of cellular function in every organ. Clinical progress in reducing the risk of ASCVD and stroke has occurred as new therapeutic strategies evolve to improve lipid profile, reduce inflammation and, moving forward, enhance the quality of lipoprotein carriers such as HDL. Oxidative Stress and Lipid Dysregulation in Lipid Droplets: A Connection to Chronic Kidney Disease Revealed in Human Kidney Cells.